Arvinas presents first-in-human data from ARV-102 trial
Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera ...
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study
Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...